Onan, E. Et Al. 2022. The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients.. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy .

Onan, E., Yasar, M., Soysal, B., & Paydas, S., (2022). The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients.. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy .

Onan, Engin Et Al. "The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients.," Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy , 2022

Onan, Engin Et Al. "The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients.." Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy , 2022

Onan, E. Et Al. (2022) . "The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients.." Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy .

@article{article, author={Engin Onan Et Al. }, title={The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients.}, journal={Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy}, year=2022}